The case in brief

This is an invented teaching case adapted from a synthetic assessment narrative. It is not a patient record or a report of a clinical outcome.

A woman has 32 months of fluctuating gastrointestinal lesions. Serial biopsies show a cytotoxic CD56-bright lymphoid population that largely preserves mucosal glands. The corresponding cells express intracellular CD3 epsilon but lack surface CD3 and surface T-cell receptor. Controlled EBER staining is negative in the atypical population; the rare positive cells are background B cells.

Her diarrhoea, weight loss and intestinal protein loss have recently worsened. The usual Ki-67 index is 25–35%, with focal areas around 60%. Current biopsies retain the earlier architecture. T-cell-receptor PCR peaks are inconsistent between samples or fail reproduction.

Bulk gastric and ileal sequencing confirms JAK3 p.Lys563_Cys565del, at variant allele fractions of 18% and 23%. Blood repeatedly contains the alteration at 0.6–0.8%; buccal DNA does not. The mutation has not been assigned to a specific cell population. A proposed JAK inhibitor is supported by a report from a different disease group: T- or NK-cell large granular lymphocytic leukaemia.

Question one: is the disease association published?

Yes. Xiao and colleagues reported the exact JAK3 K563_C565 deletion in 3 of 10 patients studied for NK-cell enteropathy. Their report also describes an NK phenotype, EBER negativity and preserved rather than destructive tissue features. This is directly relevant published precedent for the favoured indolent gastrointestinal NK-cell classification. [1]

The appropriate conclusion is positive and specific: the exact alteration is compatible with that disease. It should not be reduced to an unspecified “JAK3 gene-level association” when the exact deletion has been reported.

Question two: which cells carry it here?

The synthetic case used unfractionated samples. A gastric biopsy contains more than one kind of cell, and blood likewise contains several populations. A variant allele fraction describes the proportion of sequenced alleles carrying the change in the tested material. It is not a label identifying the cell population.

Separate testing of the atypical CD56-bright cells and other appropriately identified populations could address this assignment. If the alteration is found in the atypical cells, that connects it to the lesion. If it is found only in another population, the proposed connection is weakened. Sample purity and assay sensitivity matter when interpreting either result.

The small blood signal is therefore molecular detection in blood. Without further evidence, it is not the same thing as identifying a circulating counterpart of the gastrointestinal proliferation. A shared recurrent variant alone also does not establish tissue–blood clonal continuity.

Question three: would pathway treatment help?

JAK3 is a signalling enzyme involved in transmitting cytokine-receptor signals. An activating alteration offers a plausible biological reason to investigate pathway activity. That is a different question from whether a particular treatment improves meaningful outcomes in this disease.

A report in large granular lymphocytic leukaemia does not by itself supply that result for the gastrointestinal disorder described here. Molecular interpretation guidance separates diagnostic, prognostic and therapeutic evidence, and actionability frameworks explicitly consider the strength and setting of treatment evidence. [2] [3]

The accurate conclusion is that benefit is unestablished by the supplied rationale. It is not a demonstration that a treatment could never help.

Interpret the rest of the case at the correct level

The serial architecture, clinical course and NK-pattern phenotype favour an indolent gastrointestinal NK-cell lymphoproliferative disorder in this synthetic case. Recent protein loss is an active and consequential complication. Its seriousness should not be confused with proof of aggressive transformation.

The EBER and receptor findings also need cellular attribution. The supplied combined stains place the EBER signal in background B cells. The nonreproducible T-cell-receptor peaks do not establish that the atypical NK-pattern cells form a T-cell clone. A tissue-level molecular result cannot simply be assigned to whichever cell population is most clinically interesting.

The reasoning in one table

Question What the supplied evidence supports What would address the remaining gap
Published disease association The exact deletion has been reported in NK-cell enteropathy Verify the original study and its context
Cellular assignment in this case The alteration is present in mixed gut samples and low-level blood Test appropriately identified cell populations
Aggressive behaviour Recent clinical deterioration, with preserved serial architecture Reassess the active complication and any evolving pathological features
Treatment benefit A biological rationale and evidence from another disease cohort Relevant clinical evidence and an individual specialist assessment

What MontMedical should make easier

MontMedical provides a structured case discussion and a referenced review. In a case like this, examine whether the answer keeps these three evidence questions distinct and gives the exact published association its proper weight.

This page is an annotated editorial example, not a preserved live product output or an independent validation result. Explore a clinical case in MontMedical or read the guide to interpreting an activating alteration.